Automated System for High Yield Pancreatic Islet Isolation

高产胰岛分离自动化系统

• 批准号: 9343278
• 负责人: Lotien Richard Huang
• 金额: $ 30万
• 依托单位: CG SCIENTIFIC, INC.
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-15 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9343278
• 关键词: Affect; Benchmarking; Biological Models; Biotechnology; Cell Separation; Clinical; Collaborations; Collection; Development; Devices; Diabetes Mellitus; Diabetic mouse; Digestion; Engineering; Environment; Family suidae; Glucose; Gold; Head; Health; Human; Immunosuppression; Insulin-Dependent Diabetes Mellitus; Islets of Langerhans; Islets of Langerhans Transplantation; Laboratories; Lateral; Left; Legal patent; Massachusetts; Methods; Microfluidics; Modernization; National Institute of Diabetes and Digestive and Kidney Diseases; Nature; Neoplasm Circulating Cells; Outcome; Patients; Performance; Phase; Process; Publications; Recovery; Reproducibility; Research; Research Personnel; Science; Standardization; Sterility; System; Technology; Time; Transplantation; United States; Universities; clinical application; commercialization; cost; diabetic; hypoglycemia unawareness; improved; in vivo; invention; islet; medical schools; minimally invasive; mouse model; multidisciplinary; prototype; scale up; success

Project Summary/Abstract This project aims to develop an automated system for reproducible high-yield pancreatic islet isolation, to greatly improve islet transplantation and benefit patients who suffer type I diabetes (T1D). The new system will use state-of-the-art technologies — CG Scientific’s patent-pending automated cell isolation platform (ACIP) and its proprietary “no islet left behind” (NILB) process — to replace the nearly 30-year- old Ricordi apparatus and achieve high islet recovery, viability, function and reproducibility. The automated system will enable standardized islet isolation, and facilitate islet isolation at local laboratories to drastically reduce the damaging cold ischemic time, thereby providing islets of higher quantity and quality. These improvements will potentially allow many donor pancreata — which would otherwise be disqualified due to poor quality — to be used for islet transplantation, thereby significantly reducing the cost of islet transplantation and potentially enabling single-donor islet transplantation to become a standard therapy. In collaboration with Dr. Harlan, former Head of the Diabetes Branch at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and Drs. Greiner and Bortell, the original developers of the gold-standard diabetic NRG-Akita mouse model, CG Scientific has demonstrated that its technologies can potentially increase islet recovery by ~2.5x. Phase I of this project specifically aims to develop a scaled-up prototype device for automated islet isolation, benchmark against current standards, demonstrate its superior performance, and validate the ex vivo and in vivo functions of the isolated islets, using porcine pancreata as the model system. The successful completion of this project will result in the commercialization of a standardized, automated and high-yield islet isolation system — the first modern islet isolation system — that accelerates diabetes research and standardizes single-donor islet transplantation, thereby benefiting the 1.3 million people in the United States and the over 40 million people worldwide who suffer T1D.

项目摘要/摘要 该项目旨在开发一种自动化系统，用于可再现的高收益胰岛隔离， 极大地改善了胰岛移植和有益于患有I型糖尿病（T1D）的患者。新的 系统将使用最先进的技术 - CG科学的专利申请自动细胞隔离 平台（ACIP）及其专有的“不留下胰岛”（NILB）流程 - 取代近30年 旧的Ricordi设备并实现高胰岛恢复，活力，功能和繁殖。 自动化系统将实现标准化的胰岛隔离，并促进当地实验室的胰岛隔离 大幅度减少破坏性的缺血时间，从而提供较高数量的胰岛和 质量。这些改进可能会允许许多供体胰腺 - 否则 由于质量差而取消资格 - 用于胰岛移植，从而大大降低 胰岛移植的成本和潜在地使单位胰岛移植成为一个 标准疗法。与国家前糖尿病分支的负责人Harlan博士合作 糖尿病，消化和肾脏疾病研究所（NIDDK）和Drs。 Greiner和Bortell， 金标准糖尿病NRG-AKITA小鼠模型的原始开发商，CG Scientific具有 证明其技术可以将胰岛恢复〜2.5倍增加约2.5倍。第一阶段 项目专门旨在开发用于自动胰岛隔离的扩展原型设备，基准 根据目前的标准，证明其出色的性能，并验证离体和体内 孤立胰岛的功能，使用猪胰腺作为模型系统。成功完成 这个项目将导致标准化，自动化和高产胰岛的商业化 隔离系统（第一个现代胰岛隔离系统）加速了糖尿病研究和 标准化单位胰岛移植，从而使联合130万人受益 全球遭受T1D的州和全球超过4000万人。